Janux Therapeutics Inc. (NASDAQ: JANX) announced it will discontinue clinical development of JANX008, its EGFR-targeted cancer immunotherapy, following completion of a Phase 1a study.

The San Diego-based biopharmaceutical company completed dose escalation and expansion cohorts across multiple solid tumor indications before deciding to prioritize development resources toward other pipeline opportunities, according to a company statement.

"While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs," the company stated.

The study revealed that cytokine release syndrome occurred infrequently and was primarily limited to Grade 1 severity, allowing for outpatient dosing approval. JANX008 demonstrated fewer gastrointestinal, dermatologic, and subcutaneous adverse events compared to conventional EGFR-targeted therapies, though musculoskeletal adverse events proved dose-limiting.

"Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline," said David Campbell, the company's chief executive officer. "We evaluate each program against a high bar for safety, activity, and differentiated profile."

The discontinuation affects only JANX008 and does not impact the company's broader Tumor Activated T Cell Engager platform strategy. Janux continues to advance other clinical programs including JANX007, a PSMA-targeted therapy for prostate cancer, and JANX014, another PSMA-targeted candidate in Phase 1 trials.

The company also has JANX011, a CD19-targeted therapy being evaluated in healthy volunteers for autoimmune disease treatment.